Navigation Links
AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes
Date:6/15/2009

TUSTIN, Calif., June 15 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today the second closing of a private placement offering of "units" consisting of 12% Series 2 senior notes and warrants. The exclusive placement agent for the offering is Cantone Research Inc.

In the first closing on May 14, 2009, AMDL sold $1,327,250 of 12% Series 2 convertible notes at par value and completed the second closing on June 12, 2009, where the Company sold $468,500 of 12% Series 2 convertible notes. An aggregate of $1,658,250 in notes was sold. The notes are payable in nine principal installments and mature at the earlier of 36 months from the date of issuance or the earlier of the completion of a bank or other institutional credit facility of at least $8 million in one or more transactions for the Company's China based assets.

Warrants to purchase an aggregate of 749,600 shares of common stock were included in the units sold in the second closing. The warrants have a term of five years from the date of issuance and are exercisable at a price equal to $0.98 per share for the first closing and $1.11 for the second closing. The terms of the offering provide the exercise price of the warrants are equal to 115% of the five day volume average weighted prices (VWAP) of the Company's common stock prior to each closing date.

Cantone Research Inc. received cash commissions of $46,850, representing 10% of the principal amount of the notes purchased, $14,055 in non-accountable expenses, and five year warrants to purchase a total of 74,960 shares of common stock for the second closing, of which warrants to purchase 14,992 warrants were assigned to Galileo Asset Management, S.A. for their services in the second closing of the offering.

The net proceeds to AMDL from the total offering are being used to finance general working capital requirements, support product commercialization plans and reduce outstanding debt.

This press release does not constitute an offer or solicitation to sell or purchase any of the Company's securities. Any of the Company's securities offered will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act upon applicable exemptions from registration under the Securities Act.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs approximately 500 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward- looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of our China-based subsidiaries, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    Tel :) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HPV Vaccine Acceptability Study Announces Results
2. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
3. American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO-HOSPIRIO in Cuenca, Ecuador
4. Providence Service Corporation Announces Preliminary Results of Annual Meeting of Stockholders
5. New Online Community Answers Hospital Questions about ARRA QHR Announces Launch of theQsphere.com
6. Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts
7. PDI, Inc. Announces New Business Wins Exceeding $18 Million
8. Pulmo BioTech Inc. Announces Fund Raising Agreement with Moody Capital Solutions, Inc.
9. Eli Lilly and Company Announces New Drug Discovery Initiative
10. QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
11. NBTY Announces Preliminary Unaudited Net Sales Results for May 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, ... ... mystery. A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... in dogs. The study was published in the prestigious Journal of Veterinary Science ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is ... Awards under the Best New Product Launch category. Gensuite’s entry on their EZ ... , BOC Global Events & Training Group is a professional event and training ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
Breaking Medicine Technology: